Shares of Establishment Labs Holdings Inc. (ESTA) surged 8.01% in pre-market trading on Thursday, following the company's impressive fourth-quarter earnings report and positive outlook for its entry into the US market.
The medical device company reported a robust start in the US, generating $3.3 million in sales in the first two months of the launch, exceeding initial expectations. This strong performance, coupled with a 41% increase in total revenue for Q4 to $44.5 million driven by higher production volumes and early US sales, has bolstered investor confidence.
Furthermore, Establishment Labs has successfully onboarded over 650 accounts in the US market, with 450 placing orders and an impressive 88% reordering rate, indicating strong product acceptance. The company is on track to achieve its first positive EBITDA quarter in 2025, supported by gross margin expansion and operational efficiency improvements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.